NeuroOne Medical reports preliminary Q4 2026 revenue of $3.8M

• NeuroOne Medical Technologies (NASDAQ:NMTC) expects preliminary fiscal fourth-quarter 2026 product revenue of approximately $3.8 million, marking a 38.4% year-over-year increase.
• Expected full-year product revenue reached approximately $10.5 million, hitting the top of the company's prior $9.2 million to $10.5 million guidance range.
• The company stated that open purchase orders for shipments through fiscal first-quarter 2027 reached $5.4 million as of September 30.

NeuroOne (NASDAQ:NMTC) reported unaudited preliminary financial figures for the fiscal fourth quarter and full-year period ending September 30, 2026.

Quarterly product revenue grew to approximately $3.8 million compared to $2.7 million in the same period of fiscal 2025.

The company secured its largest purchase order ever in September valued at $4.5 million, shipping approximately $1 million during the period.

Remaining shipments from the record purchase order are scheduled to begin in fiscal first-quarter 2027 and run through the second quarter, subject to standard manufacturing timelines.

Total product orders for fiscal 2026 increased by 24.2% across active distribution channels.

Management noted that all reported revenue figures remain unaudited and subject to final year-end accounting adjustments.